Latest revenue
$10.4M
as of 2026-03-31
Latest net income
$1.9M
as of 2026-03-31
Net margin
18.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $91.6M
- Enterprise value
- $91.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $10.25
- 52-wk low
- $4.52
- Beta
- —
- Shares out
- 9.0M
5-year trend
About ICCC
Business description and risk factors will appear here once ICCC's latest filing is fully ingested.
Profitability
Gross margin
41.4%
38.1%Operating margin
6.0%
196.4%Net margin
-3.8%
53.8%Return on equity
-3.8%
51.0%Return on assets
-2.4%
48.9%Leverage
Debt / equity
0.57×
10.5%Long-term debt / equity
0.28×
15.8%Debt / assets
36.4%
6.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $10.4M | +28.4% | $1.9M | +34.2% | 18.7% |
Q4 2025 2025-12-31 | $7.6M | -1.6% | $-2.8M | -653.7% | -37.4% |
Q3 2025 2025-09-30 | $5.5M | -8.4% | $-139.7K | +80.1% | -2.5% |
Q2 2025 2025-06-30 | $6.4M | +17.8% | $501.9K | +132.8% | 7.8% |
Q1 2025 2025-03-31 | $8.1M | +11.2% | $1.4M | +430.5% | 17.9% |
Q4 2024 2024-12-31 | $7.8M | — | $514.6K | — | 6.6% |
Q3 2024 2024-09-30 | $6.0M | +11.4% | $-701.7K | +25.4% | -11.7% |
Q2 2024 2024-06-30 | $5.5M | +54.9% | $-1.5M | -11.0% | -28.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on ICCC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$102.0K
Insider selling
$0
Net activity
+$102.0K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ICCC
Institutional value
$3.7M
Total shares held
579.7K
Distinct holders
15
-11 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 260.3K | $1.6M | — | New |
| 2 | DIMENSIONAL FUND ADVISORS LP | 56.0K | $354.7K | +1.7K (+3.2%) | Added |
| 3 | Steadtrust LLC | 54.4K | $344.2K | -2.4K (-4.2%) | Trimmed |
| 4 | VANGUARD FIDUCIARY TRUST CO | 42.7K | $270.1K | — | New |
| 5 | Mesirow Financial Investment Management, Inc. | 42.5K | $268.9K | +6.0K (+16.4%) | Added |
| 6 | Strategic Financial Services, Inc. | 37.0K | $234.2K | +0 (+0.0%) | No change |
| 7 | HighTower Advisors, LLC | 24.4K | $154.2K | +5.0K (+25.8%) | Added |
| 8 | BlackRock, Inc. | 18.2K | $115.1K | +1.9K (+11.9%) | Added |
| 9 | Militia Capital Management LLC | 18.0K | $113.9K | — | New |
| 10 | Essex Financial Services, Inc. | 11.0K | $69.6K | +0 (+0.0%) | No change |
| 11 | BAILARD, INC. | 10.1K | $63.9K | — | New |
| 12 | HM PAYSON & CO | 4.0K | $25.3K | +0 (+0.0%) | No change |
| 13 | UBS Group AG | 1.1K | $7.0K | -498 (-30.9%) | Trimmed |
| 14 | WELLS FARGO & COMPANY/MN | 1 | $4 | +0 (+0.0%) | No change |
| 15 | Capital Advisors, Ltd. LLC | 98 | $1 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ICCC's latest filing finishes processing.